Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials
نویسنده
چکیده
Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials Background: Specific immunotherapy is the only treatment of IgE-mediated allergic diseases with the potential to modify the underlying cause of disease and prevent disease progression or even cure the disease. Treatment in children is therefore desirable. However, it is an open question whether immunotherapy in children and adolescents works as effective as demonstrated in adults. Objective: This post-hoc study compares the clinical efficacy and immunological response in children and adults based on two separate randomized, double-blind, placebocontrolled trials with the SQ-standardized grass allergy immunotherapy tablet (AIT) (ALK, Denmark). Methods: Children and adults were treated with grass AIT or placebo prior to and during one grass pollen season. To account for seasonal and geographical variabilities in grass pollen counts between trials, data for the peak 2 weeks of the grass pollen season has been compared. Endpoints included rhinoconjunctivitis symptom scores, medication scores and percentages well-days. Furthermore results for the entire preand co-seasonal periods of each trial in Phleum pratense-specific IgE-blocking factor and IgG4 have been compared. Results: The measured treatment efficacy during the peak grass pollen season from the pediatric and the adult trials were similar in difference relative to placebo for symptom scores (27%; 28%; p-values for both <0.01), medication scores (64%; 56%; p-values for both <0.01) and percentages of well-days (44%; 46%; p-values for both <0.01). Grass AIT induced comparable IgE-blocking factor and IgG4 responses in children and adults. All assessments were in favor of active treatment. Conclusion: Treatment with grass AIT for one grass pollen season is as efficacious in children as in adults and induces comparable immunological responses.
منابع مشابه
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
BACKGROUND Immunotherapy with the SQ-standardized grass tablet Grazax is efficacious and well-tolerated in adult patients with rhinoconjunctivitis. Allergic asthma and rhinoconjunctivitis are closely linked, and a strategy combining treatment of the upper and lower airways is recommended. OBJECTIVE To investigate the efficacy of treatment with the grass tablet on grass pollen-induced rhinocon...
متن کاملSafety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Immunotherapy is the only treatment for allergy that has the potential to alter the natural course of the disease. Sublingual immunotherapy for grass pollen-induced rhinoconjunctivitis has been developed to make immunotherapy available to a broader group of allergic patients. Here, a safe dose range and the safety during daily sublingual administration were investigated for a new tablet-based s...
متن کاملTreatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax®
Immunotherapy is the only treatment for allergy that has the potential to alter the natural course of the disease. Sublingual immunotherapy (SLIT) for grass pollen-induced rhino-conjunctivitis has been developed to make immunotherapy available to a broader group of allergic patients. In the largest clinical programme ever conducted with allergen-specific immunotherapy, over 1,700 adults and 260...
متن کاملEconomic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
BACKGROUND Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The o...
متن کاملEfficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children
Background The effect of MK-7243 (2800 BAU/75,000 SQ [~15 μg of Phleum pratense p 5], Merck/ALK-Abelló), a sublingual Timothy grass immunotherapy tablet, has been evaluated in several randomized, placebo-controlled, double-blind trials; three of these trials were conducted in adults and children in North America (the United States and Canada) who have allergic rhinitis with or without conjuncti...
متن کامل